Tom Miller, Iambic Therapeutics CEO

AI-dri­ven biotech Iambic snags $100M to en­ter the clin­ic next year in HER2 field

An­oth­er AI-dri­ven biotech has reeled in Se­ries B fund­ing, with Iambic Ther­a­peu­tics dis­clos­ing a $100 mil­lion round a week af­ter Evozyne nabbed $81 mil­lion. Both are work­ing with tech­nol­o­gy and re­ceiv­ing cap­i­tal from the com­pu­ta­tion­al pow­er­house Nvidia.

For­mer­ly known as En­tos, the oral small mol­e­cule start­up will use the funds to start its first clin­i­cal tri­al ear­ly next year, CEO Tom Miller told End­points News. Iambic had orig­i­nal­ly tar­get­ed $80 mil­lion for the round but re­ceived out­sized in­vestor in­ter­est, Miller said, not­ing the start­up’s abil­i­ty to go from pro­gram launch to IND sub­mis­sion in about 24 months.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.